Unknown

Dataset Information

0

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

ABSTRACT:

SUBMITTER: Fowler NH 

PROVIDER: S-EPMC4825296 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.

Fowler Nathan H NH   Nastoupil Loretta J LJ   Hagemeister Frederick B FB   Neelapu Sattva S SS   Fayad Luis E LE   LeBlanc Denise D   Samaniego Felipe F   Cheah Chan Yoon CY  

Haematologica 20150806 11

Similar Datasets

Unknown Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
| S-EPMC4370362 | biostudies-literature
Unknown Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.
| S-EPMC9262142 | biostudies-literature
Unknown Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
| S-EPMC5161005 | biostudies-literature
Unknown P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS
| S-EPMC9430939 | biostudies-literature
Unknown Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
| S-EPMC7391139 | biostudies-literature
Unknown Copanlisib plus rituximab combination therapy <i>vs.</i> rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis.
| S-EPMC9011241 | biostudies-literature
Unknown Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
| S-EPMC5737161 | biostudies-literature
Unknown Expanded use of rituximab in the management of non-Hodgkin lymphoma.
| S-EPMC2886316 | biostudies-literature
Unknown Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
| S-EPMC9553375 | biostudies-literature
Unknown Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.
| S-EPMC11999207 | biostudies-literature